Quantbot Technologies LP Purchases 149,272 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Quantbot Technologies LP increased its stake in Amneal Pharmaceuticals by 124.9%, owning 268,805 shares valued at approximately $2.25 million.
• Amneal Pharmaceuticals recently reported earnings of $0.23 per share, surpassing analyst expectations by $0.06, and set its FY 2025 guidance for earnings at 0.700-0.750 EPS.
• Goldman Sachs initiated coverage with a "buy" rating and a price target of $12.00, while the company's consensus target price is currently set at $11.60.

Quantbot Technologies LP boosted its stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 124.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 268,805 shares of the company's stock after purchasing an additional 149,272 shares during the quarter. Quantbot Technologies LP owned about 0.09% of AMNEAL PHARMACEUTICALS worth $2,253,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of AMRX. Legal & General Group Plc lifted its stake in AMNEAL PHARMACEUTICALS by 5.0% in the 4th quarter. Legal & General Group Plc now owns 150,709 shares of the company's stock worth $1,194,000 after purchasing an additional 7,231 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in AMNEAL PHARMACEUTICALS in the 4th quarter worth $2,946,000. Barclays PLC lifted its stake in AMNEAL PHARMACEUTICALS by 18.9% in the 4th quarter. Barclays PLC now owns 352,494 shares of the company's stock worth $2,792,000 after purchasing an additional 56,110 shares in the last quarter. XTX Topco Ltd lifted its stake in AMNEAL PHARMACEUTICALS by 75.8% in the 4th quarter. XTX Topco Ltd now owns 39,055 shares of the company's stock worth $309,000 after purchasing an additional 16,845 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in AMNEAL PHARMACEUTICALS by 2.3% in the 4th quarter. Canada Pension Plan Investment Board now owns 365,300 shares of the company's stock worth $2,893,000 after purchasing an additional 8,300 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group began coverage on shares of AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $11.60.

Insider Activity

In related news, EVP Jason B. Daly sold 22,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. This represents a 67.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 71,694 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $9.29, for a total transaction of $666,037.26. Following the transaction, the executive vice president owned 267,235 shares in the company, valued at $2,482,613.15. The trade was a 21.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 456,374 shares of company stock worth $4,239,042. 26.56% of the stock is currently owned by corporate insiders.

AMNEAL PHARMACEUTICALS Price Performance

Shares of NASDAQ AMRX traded up $0.06 during mid-day trading on Friday, hitting $9.59. 1,720,973 shares of the company's stock traded hands, compared to its average volume of 1,697,029. The company's 50-day moving average is $8.38 and its two-hundred day moving average is $8.01. The company has a market capitalization of $3.01 billion, a P/E ratio of 959.96 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a 1 year low of $6.68 and a 1 year high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Equities analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.